Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2023 07:45 ET | Source: POINT Biopharma

POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

INDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
February 02, 2023 08:30 ET | Source: POINT Biopharma

POINT Biopharma to Participate in Upcoming Investor Conferences

INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
January 12, 2023 08:30 ET | Source: POINT Biopharma

POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial

INDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
November 29, 2022 07:30 ET | Source: POINT Biopharma

POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model ...
November 14, 2022 07:15 ET | Source: POINT Biopharma

POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings

INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
November 14, 2022 07:00 ET | Source: POINT Biopharma

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticalsExpands Lantheus’ portfolio...
October 17, 2022 08:30 ET | Source: POINT Biopharma

POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual Congress

PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA...
September 16, 2022 16:30 ET | Source: POINT Biopharma

POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock

INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
September 13, 2022 21:47 ET | Source: POINT Biopharma

POINT Biopharma Prices Public Offering of Common Stock

INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
September 10, 2022 03:05 ET | Source: POINT Biopharma

POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022

Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR)...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right